Deals, Partnering

Sorrento Sells Cynviloq for $1.3B to NantPharma

Posted on 15 May 2015

Tags: ,

Sorrento Therapeutics agreed to sell its drug candidate Cynviloq (paclitaxel nanoparticle polymeric micelle) for up to $1.3 billion to NantPharma.

Sorrento said it will receive more than $90 million in upfront cash, plus up to more than $600 million in payments tied to achieving regulatory milestones, and up to another $600 million based on reaching sales milestones.

Sorrento will also receive additional transfer pricing payments from total unit sales.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

Sorrento has the option to co-develop and/or co-market Cynviloq on terms to be negotiated.

NantPharm will obtain Cynviloq by acquiring Sorrento subsidiary Igdrasol, which has been developing Cynviloq in a bio-equivalence trial.

Cynviloq is a new nanoparticle formulation of paclitaxel free of donor derived human serum albumin.

The deal for Cynviloq comes after Sorrento and NantWorks formed a global joint venture, called NANTibody, to focus on immunotherapies for cancer back in December.

Three months later in March, Sorrento entered into a global collaboration with another NantWorks company, NantCell, to discover and develop immunotherapies against tumor neo-epitopes.

Print Friendly, PDF & Email

Leave a Reply